Effectiveness of pitavastatin, an HMG-CoA reductase inhibitor, on lipid and glucose metabolism in Japanese patients with type 2 diabetes

被引：0
|
作者：
Kawai, Toshihide
Tokui, Mikiya
Funae, Osamu
Meguro, Shu
Yamada, Satoru
Tabata, Mitsuhisa
Shimada, Akira
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A461 / A461
页数：1
相关论文
共 50 条
  • [21] Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia
    Kumai, T
    Oonuma, S
    Matsumoto, N
    Takeba, Y
    Taniguchi, R
    Kamio, K
    Miyazu, O
    Koitabashi, Y
    Sekine, S
    Tadokoro, M
    Kobayashi, S
    LIFE SCIENCES, 2004, 74 (17) : 2129 - 2142
  • [22] The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes
    Scharnagl, H.
    Stojakovic, T.
    Winkler, K.
    Rosinger, S.
    Maerz, W.
    Boehm, B. O.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 (06) : 372 - 375
  • [23] Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase
    Fujino, H
    Nakai, D
    Nakagomi, R
    Saito, M
    Tokui, T
    Kojima, J
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2004, 54 (07): : 382 - 388
  • [24] Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis
    Katsumoto, M
    Shingu, T
    Kuwashima, R
    Nakata, A
    Nomura, S
    Chayama, K
    CIRCULATION JOURNAL, 2005, 69 (12) : 1547 - 1555
  • [25] HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
    Chung, YS
    Lee, MD
    Lee, SK
    Kim, HM
    Fitzpatrick, LA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03): : 1137 - 1142
  • [26] Influences of ifavastatin, a new HMG-CoA reductase inhibitor, on glucose metabolism and LDL size in patients with hyperlipidemia and NIDDM
    Yamada, N
    Saito, Y
    Akanuma, Y
    DIABETES, 2000, 49 : A422 - A422
  • [27] HMG-COA reductase inhibitor cerivastatin lowers advanced glycosylation end-products in patients with type 2 diabetes
    Scharnagl, H
    Stojakovic, T
    Winkler, K
    März, W
    Boehm, B
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 78 - 78
  • [28] Comparison in patients with type 2 diabetes of fibric acid versus HMG-CoA reductase inhibitor treatment of combined dyslipidemia
    McLaughlin, TL
    Abbasi, F
    Lamendola, CA
    Leary, E
    Reaven, GM
    DIABETES, 2002, 51 : A495 - A496
  • [29] Rosiglitazone in combination with an HMG CoA reductase inhibitor: Safety and effects on lipid profile in patients with type 2 diabetes
    Cohen, BR
    Kreider, M
    Biswas, N
    Brunzell, J
    Ratner, RE
    Freed, MI
    DIABETES, 2001, 50 : A451 - A451
  • [30] HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus
    Nakashima, A
    Nakashima, R
    Ito, T
    Masaki, T
    Yorioka, N
    DIABETIC MEDICINE, 2004, 21 (09) : 1020 - 1024
12345